Jacobio Pharmaceuticals Group Co Lt (1167) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Jacobio Pharmaceuticals Group Co Lt HK$0.93, price HK$6.06, upside -84.7%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Jacobio Pharmaceuticals Group Co Lt for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range HK$1.23 – HK$23.10 · fair‑value band HK$0.6100 – HK$1.16 · the HK$6.06 price screens above the HK$0.9300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Jacobio Pharmaceuticals Group Co Lt in your weekly email
Every Wednesday you see whether Jacobio Pharmaceuticals Group Co Lt is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China.
Show more
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors. It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. The company has a collaboration agreement with AstraZeneca AB to develop and commercialize JAB-23E73. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.
Stock analysis
Jacobio Pharmaceuticals Group Co Lt (1167) currently trades at HK$6.06, while our model-based Fair Value estimate is HK$0.9300, 84.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: HK$0.6100 (bear) to HK$1.16 (bull), the price of HK$6.06 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Jacobio Pharmaceuticals Group Co Lt reported revenue of 52.1M CNY in FY2025 versus 153M CNY in FY2021, a compound −23.6%/yr. Reported net income was −142M CNY in FY2025.
Key figures
Market cap HK$4.7B (≈ $598M) · P/S ratio 69.9 · EPS (TTM) HK$−0.0800 · Net margin −273% · Return on equity −17.2% · Return on assets (EBIT) −19.5% · Operating margin −1,292% · Revenue (TTM) 53.5M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 39% below its 52-week high and 47% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, 1167 screens richer than that median.
Fair Value models
Bear HK$0.6100Fair Value HK$0.9300Bull HK$1.16
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−66.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.0%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−209.0% (2021) → −317.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Jacobio Pharmaceuticals Group Co Lt with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 636 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside−84.7% · Bottom 25%
Profitability
Return on assets−7.8% · Above median
Growth and dividend
Revenue growth−95.0% · Bottom 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.78× · Cheaper than median
P/S (TTM)11.18× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)94· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jacobio Pharmaceuticals Group Co Lt Fair Value". https://www.fairvalue-calculator.com/stock/1167
Frequently asked questions
Is Jacobio Pharmaceuticals Group Co Lt (1167) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.9300 versus a price of HK$6.06, about −85% upside (overvalued).
What is the fair value of 1167?
Our model-based fair value for Jacobio Pharmaceuticals Group Co Lt is HK$0.9300 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$6.06.
What is the quality score of 1167?
Jacobio Pharmaceuticals Group Co Lt has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jacobio Pharmaceuticals Group Co Lt (1167)?
Our model-based price target is the fair value of HK$0.9300 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.6100, optimistic scenario HK$1.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Jacobio Pharmaceuticals Group Co Lt stock forecast for 2026?
Our models put fair value at HK$0.9300, about −85% upside versus a price of HK$6.06 (overvalued). Cautious scenario HK$0.6100, optimistic scenario HK$1.16. The calculation is refreshed regularly with new filings.
What is the revenue of Jacobio Pharmaceuticals Group Co Lt (1167)?
Jacobio Pharmaceuticals Group Co Lt reported trailing-twelve-month revenue of about 53.5M CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Jacobio Pharmaceuticals Group Co Lt (1167)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jacobio Pharmaceuticals Group Co Lt it is HK$0.9300 per share (as of Sep 27, 2026), against a price of HK$6.06. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Jacobio Pharmaceuticals Group Co Lt stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 1167 trades above its calculated fair value: price HK$6.06, fair value HK$0.9300, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1167?
No. The price is what the market pays today (HK$6.06); the fair value is what the company's own numbers justify (HK$0.9300). For Jacobio Pharmaceuticals Group Co Lt the two are HK$5.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jacobio Pharmaceuticals Group Co Lt worth?
The market values Jacobio Pharmaceuticals Group Co Lt at about HK$4.7B (market capitalisation, as of Sep 27, 2026). Per share that is HK$6.06; our models calculate a fair value of HK$0.9300 per share.
What do the bullish and bearish scenarios say about 1167?
Our models span a range for Jacobio Pharmaceuticals Group Co Lt: cautious scenario HK$0.6100, base HK$0.9300, optimistic HK$1.16 per share (as of Sep 27, 2026, price HK$6.06). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jacobio Pharmaceuticals Group Co Lt (1167)?
Balance-sheet figures for Jacobio Pharmaceuticals Group Co Lt (as of Sep 27, 2026): return on equity −17.2%, debt of 0.12 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 1167 from its 52-week high?
Jacobio Pharmaceuticals Group Co Lt trades at HK$6.06, about 39% below its 52-week high of HK$9.90 and 47% above the low of HK$4.12 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.9300 is for.
Which stocks are comparable to Jacobio Pharmaceuticals Group Co Lt?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jacobio Pharmaceuticals Group Co Lt stock attractive at the current price?
The data as of Sep 27, 2026: price HK$6.06, calculated fair value HK$0.9300 (−85%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1167 calculated?
We run Jacobio Pharmaceuticals Group Co Lt through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.9300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Jacobio Pharmaceuticals Group Co Lt itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jacobio Pharmaceuticals Group Co Lt (1167)?
The closing price on Sep 30, 2026 was HK$6.06. Our model-based fair value is HK$0.9300, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jacobio Pharmaceuticals Group Co Lt right now?
The price sits above even our optimistic bull case (HK$1.16). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.6100 to HK$1.16) leaves room in how you read the outcome.
Key figures of Jacobio Pharmaceuticals Group Co Lt
How large is the market capitalisation of Jacobio Pharmaceuticals Group Co Lt (1167)?
The market capitalisation of Jacobio Pharmaceuticals Group Co Lt is HK$4.7B (≈ $598M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jacobio Pharmaceuticals Group Co Lt (1167)?
The price-to-sales ratio of Jacobio Pharmaceuticals Group Co Lt is 69.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jacobio Pharmaceuticals Group Co Lt (1167)?
Earnings per share at Jacobio Pharmaceuticals Group Co Lt are HK$−0.0800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Jacobio Pharmaceuticals Group Co Lt (1167)?
The net margin of Jacobio Pharmaceuticals Group Co Lt is −273% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jacobio Pharmaceuticals Group Co Lt (1167)?
The return on equity (ROE) of Jacobio Pharmaceuticals Group Co Lt is −17.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jacobio Pharmaceuticals Group Co Lt (1167)?
On an EBIT basis the return on assets of Jacobio Pharmaceuticals Group Co Lt is −19.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jacobio Pharmaceuticals Group Co Lt (1167)?
The operating margin of Jacobio Pharmaceuticals Group Co Lt is −1,292% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jacobio Pharmaceuticals Group Co Lt (1167)?
Revenue at Jacobio Pharmaceuticals Group Co Lt is growing −95.0% versus a year earlier (3y avg −18.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Jacobio Pharmaceuticals Group Co Lt (1167) generate?
The free cash flow of Jacobio Pharmaceuticals Group Co Lt is −187M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Jacobio Pharmaceuticals Group Co Lt (1167) hold?
Jacobio Pharmaceuticals Group Co Lt holds more cash than debt, 778M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Jacobio Pharmaceuticals Group Co Lt in the live analysis
One click puts Jacobio Pharmaceuticals Group Co Lt on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026